{
    "고삼": {
        "2 -methoxykurarinone": {
            "PubChem ID": "11982641",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c2c1C(=O)CC(O2)c1ccc(cc1OC)O)CC(C(=C)C)CC=C(C)C",
                "Formula": "C27H32O6",
                "Molecular weight": "452.54 g/mol",
                "Num. heavy atoms": "33",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.37",
                "Num. rotatable bonds": "8",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "2",
                "Molar Refractivity": "129.81",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "85.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.40",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.88",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.59",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.68",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "6.07",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.72",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.09",
                "Solubility": "9.52e-05 mg/ml ; 2.10e-07 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.44",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-6.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.89 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.67"
            }
        },
        "3 ,7-dihydroxy-\n4 -methoxy-isoflavone": {
            "PubChem ID": "14504257",
            "SMILES": "CC(C)(CCC1=C(C(=CC(=C1OC)O)O)C2=COC3=C(C2=O)C=CC(=C3)O)O",
            "Molecular Data": {
                "SMILES": "COc1c(O)cc(c(c1CCC(O)(C)C)c1coc2c(c1=O)ccc(c2)O)O",
                "Formula": "C21H22O7",
                "Molecular weight": "386.40 g/mol",
                "Num. heavy atoms": "28",
                "Num. arom. heavy atoms": "16",
                "Fraction Csp3": "0.29",
                "Num. rotatable bonds": "5",
                "Num. H-bond acceptors": "7",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "105.87",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "120.36 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.36",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "2.64",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "3.29",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.59",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "3.68",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "2.51",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-3.99",
                "Solubility": "1.16e-03 mg/ml ; 3.01e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-4.82",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.52",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.78 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW>350",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.61"
            }
        },
        "7,11-Dehydromatrin": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "7,4 -dihydroxy-5-methoxy-8-( , -dimethylallyl)-flavanone (": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "7a-Hydroxysophoramine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "9a-Hydroxymatrine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "9a-Hydroxysophocarpine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "9a-Hydroxysophoramine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Anagyrine": {
            "PubChem ID": "5351589",
            "SMILES": "C1CCN2CC3CC(C2C1)CN4C3=CC=CC4=O",
            "Molecular Data": {
                "SMILES": "O=c1cccc2n1CC1CC2CN2C1CCCC2",
                "Formula": "C15H20N2O",
                "Molecular weight": "244.33 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.67",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "75.86",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "25.24 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.60",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.56",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.44",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.38",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.62",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.92",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.58",
                "Solubility": "7.28e-01 mg/ml ; 2.98e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.70",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.53",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.68 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.77"
            }
        },
        "Baptifoline": {
            "PubChem ID": "118701431",
            "SMILES": "C1CN2CC3CC(C2CC1O)CN4C3=CC=CC4=O",
            "Molecular Data": {
                "SMILES": "OC1CCN2C(C1)C1CC(C2)c2n(C1)c(=O)ccc2",
                "Formula": "C15H20N2O2",
                "Molecular weight": "260.33 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.67",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "77.02",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "45.47 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.33",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.59",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.41",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.53",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.69",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.11",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.06",
                "Solubility": "4.98e+00 mg/ml ; 1.91e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.12",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.72",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.47 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.91"
            }
        },
        "Cytisine": {
            "PubChem ID": "10235",
            "SMILES": "C1C2CNCC1C3=CC=CC(=O)N3C2",
            "Molecular Data": {
                "SMILES": "O=c1cccc2n1CC1CNCC2C1",
                "Formula": "C11H14N2O",
                "Molecular weight": "190.24 g/mol",
                "Num. heavy atoms": "14",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.55",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "58.65",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "34.03 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.87",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.18",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.17",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.30",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.28",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.96",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.45",
                "Solubility": "8.30e-01 mg/ml ; 4.37e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-0.45",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.36",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.33 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: MW<200",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.54"
            }
        },
        "formononetin": {
            "PubChem ID": "5280378",
            "SMILES": "COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O",
            "Molecular Data": {
                "SMILES": "COc1ccc(cc1)c1coc2c(c1=O)ccc(c2)O",
                "Formula": "C16H12O4",
                "Molecular weight": "268.26 g/mol",
                "Num. heavy atoms": "20",
                "Num. arom. heavy atoms": "16",
                "Fraction Csp3": "0.06",
                "Num. rotatable bonds": "2",
                "Num. H-bond acceptors": "4",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "76.43",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "59.67 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.49",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "2.80",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "3.17",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.33",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "3.52",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "2.66",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-3.73",
                "Solubility": "5.58e-04 mg/ml ; 2.08e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-3.71",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.95 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "2.81"
            }
        },
        "Isokuraramine": {
            "PubChem ID": "101665417",
            "SMILES": "CN1CC(CC(C1)C2=CC=CC(=O)N2)CO",
            "Molecular Data": {
                "SMILES": "OCC1CN(C)CC(C1)c1cccc(=O)[nH]1",
                "Formula": "C12H18N2O2",
                "Molecular weight": "222.28 g/mol",
                "Num. heavy atoms": "16",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.58",
                "Num. rotatable bonds": "2",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "2",
                "Molar Refractivity": "66.73",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "56.33 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.92",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.01",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.02",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.73",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.63",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.86",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.37",
                "Solubility": "8.45e-01 mg/ml ; 3.80e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-0.74",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.42",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.65 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "2.96"
            }
        },
        "isokurarinone": {
            "PubChem ID": "5318581",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=C(C=C(C=C3)O)OC)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)ccc1C1CC(=O)c2c(O1)c(CC(C(=C)C)CC=C(C)C)c(cc2O)O",
                "Formula": "C26H30O6",
                "Molecular weight": "438.51 g/mol",
                "Num. heavy atoms": "32",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.35",
                "Num. rotatable bonds": "7",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "3",
                "Molar Refractivity": "125.34",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "96.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.38",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "6.10",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.29",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.48",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "5.50",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.55",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.22",
                "Solubility": "4.50e-04 mg/ml ; 1.03e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.90",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.99",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.64 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.55"
            }
        },
        "Isomatrine": {
            "PubChem ID": "5271984",
            "SMILES": "C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H24N2O",
                "Molecular weight": "248.36 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.59",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.66",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.58",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.27",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.34",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.79",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.38",
                "Solubility": "5.17e+00 mg/ml ; 2.08e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.69 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.20"
            }
        },
        "Isosophocarpine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "isoxanthohumol": {
            "PubChem ID": "513197",
            "SMILES": "CC(=CCC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=CC=C(C=C3)O)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c2c1C(=O)CC(O2)c1ccc(cc1)O)CC=C(C)C",
                "Formula": "C21H22O5",
                "Molecular weight": "354.40 g/mol",
                "Num. heavy atoms": "26",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.29",
                "Num. rotatable bonds": "4",
                "Num. H-bond acceptors": "5",
                "Num. H-bond donors": "2",
                "Molar Refractivity": "99.76",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "75.99 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.06",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "4.09",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.00",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.04",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.29",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.50",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-4.69",
                "Solubility": "1.59e-03 mg/ml ; 4.49e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-5.39",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.35",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "Yes",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.56 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.79"
            }
        },
        "kosamol R": {
            "PubChem ID": "102506430",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C(=C1O)CCC(C)(C)O)O)C(=O)C(C(O2)C3=C(C=C(C=C3)O)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "CC(=CCC(C(=C)C)Cc1c2OC(c3ccc(cc3O)O)C(C(=O)c2c(c(c1O)CCC(O)(C)C)O)O)C",
                "Formula": "C30H38O8",
                "Molecular weight": "526.62 g/mol",
                "Num. heavy atoms": "38",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.43",
                "Num. rotatable bonds": "9",
                "Num. H-bond acceptors": "8",
                "Num. H-bond donors": "6",
                "Molar Refractivity": "147.43",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "147.68 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.85",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.78",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.66",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.68",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "5.35",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.26",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.39",
                "Solubility": "1.90e-03 mg/ml ; 3.61e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-8.65",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.44",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.41 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "No; 2 violations: MW>500, NHorOH>5",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 3 violations: MW>480, MR>130, #atoms>70",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "No; 1 violation: TPSA>140",
                "Egan \n                    Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "No; 1 violation: TPSA>131.6",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 2 violations: XLOGP3>5, H-don>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.17",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "5.36"
            }
        },
        "Kuraramine": {
            "PubChem ID": "11447394",
            "SMILES": "CN1CC(CC(C1)C2=CC=CC(=O)N2)CO",
            "Molecular Data": {
                "SMILES": "OCC1CN(C)CC(C1)c1cccc(=O)[nH]1",
                "Formula": "C12H18N2O2",
                "Molecular weight": "222.28 g/mol",
                "Num. heavy atoms": "16",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.58",
                "Num. rotatable bonds": "2",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "2",
                "Molar Refractivity": "66.73",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "56.33 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.92",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.01",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.02",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.73",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.63",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.86",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.37",
                "Solubility": "8.45e-01 mg/ml ; 3.80e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-0.74",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.42",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.65 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "2.96"
            }
        },
        "kuraridine": {
            "PubChem ID": "9954815",
            "SMILES": "CC(=CCC(CC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=C(C=C(C=C2)O)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c(c1C(=O)C=Cc1ccc(cc1O)O)O)CC(C(=C)C)CC=C(C)C",
                "Formula": "C26H30O6",
                "Molecular weight": "438.51 g/mol",
                "Num. heavy atoms": "32",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.27",
                "Num. rotatable bonds": "9",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "128.11",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "107.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.57",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "6.54",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.40",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.80",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "5.58",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.78",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.36",
                "Solubility": "2.62e-03 mg/ml ; 5.97e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-8.59",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.22",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.33 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "2 alerts: isolated_alkene, michael_acceptor_1",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.33"
            }
        },
        "kuraridinol": {
            "PubChem ID": "5318880",
            "SMILES": "CC(=C)C(CCC(C)(C)O)CC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=C(C=C(C=C2)O)O)O",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c(c1C(=O)C=Cc1ccc(cc1O)O)O)CC(C(=C)C)CCC(O)(C)C",
                "Formula": "C26H32O7",
                "Molecular weight": "456.53 g/mol",
                "Num. heavy atoms": "33",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.35",
                "Num. rotatable bonds": "10",
                "Num. H-bond acceptors": "7",
                "Num. H-bond donors": "5",
                "Molar Refractivity": "129.79",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "127.45 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.15",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.22",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.59",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.07",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "5.00",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.01",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.57",
                "Solubility": "4.63e-03 mg/ml ; 1.01e-05 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.64",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-4.99",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.38 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "2 alerts: isolated_alkene, michael_acceptor_1",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.40"
            }
        },
        "kurarinol": {
            "PubChem ID": "44563198",
            "SMILES": "CC(=C)C(CCC(C)(C)O)CC1=C2C(=C(C=C1O)OC)C(=O)CC(O2)C3=C(C=C(C=C3)O)O",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c2c1C(=O)CC(O2)c1ccc(cc1O)O)CC(C(=C)C)CCC(O)(C)C",
                "Formula": "C26H32O7",
                "Molecular weight": "456.53 g/mol",
                "Num. heavy atoms": "33",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.42",
                "Num. rotatable bonds": "8",
                "Num. H-bond acceptors": "7",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "127.02",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "116.45 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.90",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "4.24",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.48",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.76",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.92",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.66",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.08",
                "Solubility": "7.95e-04 mg/ml ; 1.74e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-6.40",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.76",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.07 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.64"
            }
        },
        "kurarinone": {
            "PubChem ID": "9954815",
            "SMILES": "CC(=CCC(CC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=C(C=C(C=C2)O)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c(c1C(=O)C=Cc1ccc(cc1O)O)O)CC(C(=C)C)CC=C(C)C",
                "Formula": "C26H30O6",
                "Molecular weight": "438.51 g/mol",
                "Num. heavy atoms": "32",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.27",
                "Num. rotatable bonds": "9",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "128.11",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "107.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.57",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "6.54",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.40",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.80",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "5.58",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.78",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.36",
                "Solubility": "2.62e-03 mg/ml ; 5.97e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-8.59",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.22",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.33 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "2 alerts: isolated_alkene, michael_acceptor_1",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.33"
            }
        },
        "kushecarpin A": {
            "PubChem ID": "10495761",
            "SMILES": "COC1C2C(C3(CCC(=O)C=C3O1)O)OC4=C2C=CC(=C4)OC",
            "Molecular Data": {
                "SMILES": "COC1OC2=CC(=O)CCC2(C2C1c1ccc(cc1O2)OC)O",
                "Formula": "C17H18O6",
                "Molecular weight": "318.32 g/mol",
                "Num. heavy atoms": "23",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.47",
                "Num. rotatable bonds": "2",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "79.60",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "74.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.42",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.62",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.52",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.42",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.70",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.34",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.27",
                "Solubility": "3.44e-01 mg/ml ; 1.08e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.75",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.97",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.80 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.85",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.70"
            }
        },
        "kushenol A": {
            "PubChem ID": "5318890",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=CC=CC=C3O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "CC(=CCC(C(=C)C)Cc1c(O)cc(c2c1OC(CC2=O)c1ccccc1O)O)C",
                "Formula": "C25H28O5",
                "Molecular weight": "408.49 g/mol",
                "Num. heavy atoms": "30",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.32",
                "Num. rotatable bonds": "6",
                "Num. H-bond acceptors": "5",
                "Num. H-bond donors": "3",
                "Molar Refractivity": "118.85",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "86.99 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.40",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "6.13",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.28",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.82",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "5.42",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.61",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.13",
                "Solubility": "5.27e-04 mg/ml ; 1.29e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.74",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.89",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.44 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.40"
            }
        },
        "kushenol C": {
            "PubChem ID": "5481237",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)O)C(=O)C(=C(O2)C3=C(C=C(C=C3)O)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "CC(=CCC(C(=C)C)Cc1c(O)cc(c2c1oc(c1ccc(cc1O)O)c(c2=O)O)O)C",
                "Formula": "C25H26O7",
                "Molecular weight": "438.47 g/mol",
                "Num. heavy atoms": "32",
                "Num. arom. heavy atoms": "16",
                "Fraction Csp3": "0.24",
                "Num. rotatable bonds": "6",
                "Num. H-bond acceptors": "7",
                "Num. H-bond donors": "5",
                "Molar Refractivity": "125.32",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "131.36 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.13",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.28",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.08",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.56",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.94",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.00",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.86",
                "Solubility": "8.83e-04 mg/ml ; 2.01e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.79",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.70",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.23 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.69"
            }
        },
        "kushenol D": {
            "PubChem ID": "5318893",
            "SMILES": "CC(=CCC(CC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=C(C=C(C=C2)O)OC)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c(c1C(=O)C=Cc1ccc(cc1OC)O)O)CC(C(=C)C)CC=C(C)C",
                "Formula": "C27H32O6",
                "Molecular weight": "452.54 g/mol",
                "Num. heavy atoms": "33",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.30",
                "Num. rotatable bonds": "10",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "3",
                "Molar Refractivity": "132.58",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "96.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.55",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "6.86",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "5.70",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "3.00",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "6.14",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "5.05",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.58",
                "Solubility": "5.54e-04 mg/ml ; 1.22e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-8.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.91",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.19 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 2 violations: WLOGP>5.6, MR>130",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "2 alerts: isolated_alkene, michael_acceptor_1",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 3 violations: MW>350, Rotors>7, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.46"
            }
        },
        "kushenol I/N": {
            "PubChem ID": "102004822",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)OC)C(=O)C(C(O2)C3=C(C=C(C=C3)O)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c2c1C(=O)C(O)C(O2)c1ccc(cc1O)O)CC(C(=C)C)CC=C(C)C",
                "Formula": "C26H30O7",
                "Molecular weight": "454.51 g/mol",
                "Num. heavy atoms": "33",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.35",
                "Num. rotatable bonds": "7",
                "Num. H-bond acceptors": "7",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "126.51",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "116.45 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.84",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.00",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.26",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.68",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.62",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.68",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.62",
                "Solubility": "3.09e-03 mg/ml ; 6.81e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.19",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.17",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.52 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.85"
            }
        },
        "kushenol O": {
            "PubChem ID": "44257224",
            "SMILES": "COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)OC4C(C(C(C(O4)COC5C(C(C(CO5)O)O)O)O)O)O",
            "Molecular Data": {
                "SMILES": "COc1ccc(cc1)c1coc2c(c1=O)ccc(c2)OC1OC(COC2OCC(C(C2O)O)O)C(C(C1O)O)O",
                "Formula": "C27H30O13",
                "Molecular weight": "562.52 g/mol",
                "Num. heavy atoms": "40",
                "Num. arom. heavy atoms": "16",
                "Fraction Csp3": "0.44",
                "Num. rotatable bonds": "7",
                "Num. H-bond acceptors": "13",
                "Num. H-bond donors": "6",
                "Molar Refractivity": "134.97",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "197.74 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.01",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "-1.09",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "-0.89",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "-2.48",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-0.27",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "-0.34",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.47",
                "Solubility": "1.35e+00 mg/ml ; 2.39e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-2.57",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.62",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-10.51 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "No; 3 violations: MW>500, NorO>10, NHorOH>5",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 3 violations: MW>480, WLOGP<-0.4, MR>130",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "No; 1 violation: TPSA>140",
                "Egan \n                    Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "No; 1 violation: TPSA>131.6",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 3 violations: TPSA>150, H-acc>10, H-don>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.17",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW>350",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "6.14"
            }
        },
        "Lamprolobine": {
            "PubChem ID": "87752",
            "SMILES": "C1CCN2CCCC(C2C1)CN3C(=O)CCCC3=O",
            "Molecular Data": {
                "SMILES": "O=C1CCCC(=O)N1CC1CCCN2C1CCCC2",
                "Formula": "C15H24N2O2",
                "Molecular weight": "264.36 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.87",
                "Num. rotatable bonds": "2",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "81.90",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "40.62 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.78",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.20",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.03",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.71",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.78",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.70",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.10",
                "Solubility": "1.82e+00 mg/ml ; 6.89e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.65",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.16",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.06 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: phthalimide",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.01"
            }
        },
        "Leontalbinine N-oxide": {
            "PubChem ID": "126455735",
            "SMILES": "C1CC2CN3C(=C4C2[N+](C1)(CCC4)[O-])CCCC3=O",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2=C3C4C(CN12)CCC[N+]4([O-])CCC3",
                "Formula": "C15H22N2O2",
                "Molecular weight": "262.35 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.80",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "82.48",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "49.74 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.73",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.35",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.39",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.28",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.67",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.42",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.69",
                "Solubility": "1.46e+00 mg/ml ; 5.57e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-0.96",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.25",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.65 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: quaternary_nitrogen_2",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.51"
            }
        },
        "Lupanine": {
            "PubChem ID": "12310653",
            "SMILES": "C1CCN2CC3CC(C2C1)CN4C3CCCC4=O",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CC2CN2C1CCCC2",
                "Formula": "C15H24N2O",
                "Molecular weight": "248.36 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.58",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.69",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.58",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.27",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.34",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.80",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.38",
                "Solubility": "5.17e+00 mg/ml ; 2.08e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.69 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.20"
            }
        },
        "maackiain": {
            "PubChem ID": "363863",
            "SMILES": "C1C2C(C3=C(O1)C=C(C=C3)O)OC4=CC5=C(C=C24)OCO5",
            "Molecular Data": {
                "SMILES": "Oc1ccc2c(c1)OCC1C2Oc2c1cc1c(c2)OCO1",
                "Formula": "C16H12O5",
                "Molecular weight": "284.26 g/mol",
                "Num. heavy atoms": "21",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.25",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "5",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "72.74",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "57.15 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.77",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "2.61",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "2.41",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.71",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "2.60",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "2.42",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-3.67",
                "Solubility": "3.33e-02 mg/ml ; 1.17e-04 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-3.46",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-3.93",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "Yes",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.18 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.70"
            }
        },
        "Mamanine": {
            "PubChem ID": "3085182",
            "SMILES": "C1CCN2CC(CC(C2C1)CO)C3=CC=CC(=O)N3",
            "Molecular Data": {
                "SMILES": "OCC1CC(CN2C1CCCC2)c1cccc(=O)[nH]1",
                "Formula": "C15H22N2O2",
                "Molecular weight": "262.35 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.67",
                "Num. rotatable bonds": "2",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "2",
                "Molar Refractivity": "79.04",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "56.33 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.48",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.92",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.94",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.53",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "2.10",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.59",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.15",
                "Solubility": "3.26e-01 mg/ml ; 1.24e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.91",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.25 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.57"
            }
        },
        "matrine": {
            "PubChem ID": "91466",
            "SMILES": "C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H24N2O",
                "Molecular weight": "248.36 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.59",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.66",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.58",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.27",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.34",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.79",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.38",
                "Solubility": "5.17e+00 mg/ml ; 2.08e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.69 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.20"
            }
        },
        "Matrine": {
            "PubChem ID": "91466",
            "SMILES": "C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H24N2O",
                "Molecular weight": "248.36 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.59",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.66",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.58",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.27",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.34",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.79",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.38",
                "Solubility": "5.17e+00 mg/ml ; 2.08e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.69 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.20"
            }
        },
        "N-methyIcytisine": {
            "PubChem ID": "670971",
            "SMILES": "CN1CC2CC(C1)C3=CC=CC(=O)N3C2",
            "Molecular Data": {
                "SMILES": "CN1CC2CC(C1)c1n(C2)c(=O)ccc1",
                "Formula": "C12H16N2O",
                "Molecular weight": "204.27 g/mol",
                "Num. heavy atoms": "15",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.58",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "63.55",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "25.24 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.23",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.65",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.52",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.59",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.16",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.23",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.81",
                "Solubility": "1.88e+00 mg/ml ; 9.23e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-0.76",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.04",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.08 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.64"
            }
        },
        "norkurarinol/kosamol Q": {
            "PubChem ID": "12146484",
            "SMILES": "CC(=C)C(CCC(C)(C)O)CC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=C(C=C(C=C3)O)O",
            "Molecular Data": {
                "SMILES": "Oc1ccc(c(c1)O)C1CC(=O)c2c(O1)c(CC(C(=C)C)CCC(O)(C)C)c(cc2O)O",
                "Formula": "C25H30O7",
                "Molecular weight": "442.50 g/mol",
                "Num. heavy atoms": "32",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.40",
                "Num. rotatable bonds": "7",
                "Num. H-bond acceptors": "7",
                "Num. H-bond donors": "5",
                "Molar Refractivity": "122.55",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "127.45 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.81",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "4.46",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.18",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.55",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.36",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.47",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.21",
                "Solubility": "3.76e-03 mg/ml ; 8.49e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-6.86",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.07",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.83 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.52"
            }
        },
        "Oxy sophocarpine": {
            "PubChem ID": "618688",
            "SMILES": "C1CC2CN3C(CC=CC3=O)C4C2[N+](C1)(CCC4)[O-]",
            "Molecular Data": {
                "SMILES": "O=C1C=CCC2N1CC1CCC[N+]3(C1C2CCC3)[O-]",
                "Formula": "C15H22N2O2",
                "Molecular weight": "262.35 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.80",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "82.48",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "49.74 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.47",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.25",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.90",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.28",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.46",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.29",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.25",
                "Solubility": "1.16e+01 mg/ml ; 4.42e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.89",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.35",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.01 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: quaternary_nitrogen_2",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.46"
            }
        },
        "oxymatrine": {
            "PubChem ID": "114850",
            "SMILES": "C1CC2C3CCC[N+]4(C3C(CCC4)CN2C(=O)C1)[O-]",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCC[N+]3(C1C2CCC3)[O-]",
                "Formula": "C15H24N2O2",
                "Molecular weight": "264.36 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "82.95",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "49.74 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.50",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.11",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.12",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.39",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.05",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.41",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.18",
                "Solubility": "3.97e+00 mg/ml ; 1.50e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.75",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.82",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.12 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: quaternary_nitrogen_2",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.50"
            }
        },
        "Oxymatrine": {
            "PubChem ID": "114850",
            "SMILES": "C1CC2C3CCC[N+]4(C3C(CCC4)CN2C(=O)C1)[O-]",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCC[N+]3(C1C2CCC3)[O-]",
                "Formula": "C15H24N2O2",
                "Molecular weight": "264.36 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "82.95",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "49.74 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.50",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.11",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.12",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.39",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.05",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.41",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.18",
                "Solubility": "3.97e+00 mg/ml ; 1.50e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.75",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.82",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.12 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: quaternary_nitrogen_2",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.50"
            }
        },
        "sophocarpine": {
            "PubChem ID": "115269",
            "SMILES": "C1CC2CN3C(CC=CC3=O)C4C2N(C1)CCC4",
            "Molecular Data": {
                "SMILES": "O=C1C=CCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H22N2O",
                "Molecular weight": "246.35 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.80",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.11",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.61",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.72",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.89",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.16",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.94",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.66",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.45",
                "Solubility": "1.51e+01 mg/ml ; 6.11e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.83",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.21",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.58 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.38"
            }
        },
        "Sophocarpine": {
            "PubChem ID": "115269",
            "SMILES": "C1CC2CN3C(CC=CC3=O)C4C2N(C1)CCC4",
            "Molecular Data": {
                "SMILES": "O=C1C=CCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H22N2O",
                "Molecular weight": "246.35 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.80",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.11",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.61",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.72",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.89",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.16",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.94",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.66",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.45",
                "Solubility": "1.51e+01 mg/ml ; 6.11e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.83",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.21",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.58 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.38"
            }
        },
        "sophoraflavanone G": {
            "PubChem ID": "9910234",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=C(C=C(C=C3)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "CC(=CCC(C(=C)C)Cc1c(O)cc(c2c1OC(CC2=O)c1ccc(cc1O)O)O)C",
                "Formula": "C25H28O6",
                "Molecular weight": "424.49 g/mol",
                "Num. heavy atoms": "31",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.32",
                "Num. rotatable bonds": "6",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "120.87",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "107.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.20",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.78",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.98",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.28",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.95",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.24",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.00",
                "Solubility": "2.13e-03 mg/ml ; 5.02e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.80",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.30",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.79 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.44"
            }
        },
        "sophoraflavanoneG": {
            "PubChem ID": "9910234",
            "SMILES": "CC(=CCC(CC1=C2C(=C(C=C1O)O)C(=O)CC(O2)C3=C(C=C(C=C3)O)O)C(=C)C)C",
            "Molecular Data": {
                "SMILES": "CC(=CCC(C(=C)C)Cc1c(O)cc(c2c1OC(CC2=O)c1ccc(cc1O)O)O)C",
                "Formula": "C25H28O6",
                "Molecular weight": "424.49 g/mol",
                "Num. heavy atoms": "31",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.32",
                "Num. rotatable bonds": "6",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "120.87",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "107.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.20",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.78",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.98",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.28",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.95",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.24",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-6.00",
                "Solubility": "2.13e-03 mg/ml ; 5.02e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-7.80",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.30",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.79 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "4.44"
            }
        },
        "sophoraisoflavanone\nA": {
            "PubChem ID": "442822",
            "SMILES": "CC(=CCC1=C(C=CC(=C1OC)C2COC3=CC(=CC(=C3C2=O)O)O)O)C",
            "Molecular Data": {
                "SMILES": "COc1c(ccc(c1CC=C(C)C)O)C1COc2c(C1=O)c(O)cc(c2)O",
                "Formula": "C21H22O6",
                "Molecular weight": "370.40 g/mol",
                "Num. heavy atoms": "27",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.29",
                "Num. rotatable bonds": "4",
                "Num. H-bond acceptors": "6",
                "Num. H-bond donors": "3",
                "Molar Refractivity": "101.78",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "96.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.10",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "4.46",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "3.68",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.50",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "3.81",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.31",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.01",
                "Solubility": "6.42e-03 mg/ml ; 1.73e-05 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-6.20",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-4.76",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-5.39 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.98"
            }
        },
        "Sophoranol": {
            "PubChem ID": "12442899",
            "SMILES": "C1CC2C3CCCN4C3C(CCC4)(CN2C(=O)C1)O",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1(O)CCCN3C1C2CCC3",
                "Formula": "C15H24N2O2",
                "Molecular weight": "264.36 g/mol",
                "Num. heavy atoms": "19",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "80.78",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "43.78 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.36",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.52",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.22",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.42",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.81",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.07",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.81",
                "Solubility": "1.26e+01 mg/ml ; 4.75e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.01",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.32",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-7.54 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "Yes",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.42"
            }
        },
        "sophoridine": {
            "PubChem ID": "165549",
            "SMILES": "C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H24N2O",
                "Molecular weight": "248.36 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.59",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.66",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.58",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.27",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.34",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.79",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.38",
                "Solubility": "5.17e+00 mg/ml ; 2.08e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.69 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.20"
            }
        },
        "Sophoridine": {
            "PubChem ID": "165549",
            "SMILES": "C1CC2C3CCCN4C3C(CCC4)CN2C(=O)C1",
            "Molecular Data": {
                "SMILES": "O=C1CCCC2N1CC1CCCN3C1C2CCC3",
                "Formula": "C15H24N2O",
                "Molecular weight": "248.36 g/mol",
                "Num. heavy atoms": "18",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.93",
                "Num. rotatable bonds": "0",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "0",
                "Molar Refractivity": "79.59",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "23.55 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.66",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.58",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.27",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.34",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.79",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-2.38",
                "Solubility": "5.17e+00 mg/ml ; 2.08e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.69",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.68",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.69 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.20"
            }
        },
        "trifolirhizin": {
            "PubChem ID": "442827",
            "SMILES": "C1C2C(C3=C(O1)C=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)OC5=CC6=C(C=C25)OCO6",
            "Molecular Data": {
                "SMILES": "OCC1OC(Oc2ccc3c(c2)OCC2C3Oc3c2cc2c(c3)OCO2)C(C(C1O)O)O",
                "Formula": "C22H22O10",
                "Molecular weight": "446.40 g/mol",
                "Num. heavy atoms": "32",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.45",
                "Num. rotatable bonds": "3",
                "Num. H-bond acceptors": "10",
                "Num. H-bond donors": "4",
                "Molar Refractivity": "104.86",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "136.30 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.83",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.81",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "-0.12",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "-0.45",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.35",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.68",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-3.20",
                "Solubility": "2.75e+00 mg/ml ; 6.15e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-3.25",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.21",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-8.45 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                    Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "No; 1 violation: TPSA>131.6",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW>350",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "5.29"
            }
        },
        "trifolirhizin-6  -malonate": {
            "PubChem ID": "90658672",
            "SMILES": "C1C2C(C3=C(O1)C=C(C=C3)OC4C(C(C(C(O4)COC(=O)CC(=O)[O-])O)O)O)OC5=CC6=C(C=C25)OCO6",
            "Molecular Data": {
                "SMILES": "[O-]C(=O)CC(=O)OCC1OC(Oc2ccc3c(c2)OCC2C3Oc3c2cc2c(c3)OCO2)C(C(C1O)O)O",
                "Formula": "C25H23O13-",
                "Molecular weight": "531.44 g/mol",
                "Num. heavy atoms": "38",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.44",
                "Num. rotatable bonds": "7",
                "Num. H-bond acceptors": "13",
                "Num. H-bond donors": "3",
                "Molar Refractivity": "119.23",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "182.50 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.01",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.52",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "-1.43",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "-0.61",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.17",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.13",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-3.23",
                "Solubility": "3.69e+00 mg/ml ; 6.95e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-3.92",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.16",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-9.17 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "No; 2 violations: MW>500, NorO>10",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 2 violations: MW>480, WLOGP<-0.4",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "No; 1 violation: TPSA>140",
                "Egan \n                    Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "No; 1 violation: TPSA>131.6",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 2 violations: TPSA>150, H-acc>10",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.11",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: beta_keto_anhydride",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW>350",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "5.55"
            }
        },
        "xanthohumol": {
            "PubChem ID": "639665",
            "SMILES": "CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C",
            "Molecular Data": {
                "SMILES": "COc1cc(O)c(c(c1C(=O)C=Cc1ccc(cc1)O)O)CC=C(C)C",
                "Formula": "C21H22O5",
                "Molecular weight": "354.40 g/mol",
                "Num. heavy atoms": "26",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.19",
                "Num. rotatable bonds": "6",
                "Num. H-bond acceptors": "5",
                "Num. H-bond donors": "3",
                "Molar Refractivity": "102.53",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "86.99 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.93",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "5.07",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.11",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "2.36",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.31",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.76",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.18",
                "Solubility": "9.26e-03 mg/ml ; 2.61e-05 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-6.64",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-4.58",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.86 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: XLOGP3>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "2 alerts: isolated_alkene, michael_acceptor_1",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.16"
            }
        },
        "": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "25mg (추출물중량)": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "정보 없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "linear 51-80 % of B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.5g (건조중량)": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "linear 10-30% of B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "1g (건조중량)": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "100°C": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "2.5g (건조중량)": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "linear 94-68% of B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    },
    "지모": {
        "3''-hydroxy-4''-methoxy-4''-dehydroxynyasol": {
            "PubChem ID": "21575014",
            "SMILES": "COC1=C(C=C(C=C1)C(C=C)C=CC2=CC=C(C=C2)O)O",
            "Molecular Data": {
                "SMILES": "C=CC(c1ccc(c(c1)O)OC)C=Cc1ccc(cc1)O",
                "Formula": "C18H18O3",
                "Molecular weight": "282.33 g/mol",
                "Num. heavy atoms": "21",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.11",
                "Num. rotatable bonds": "5",
                "Num. H-bond acceptors": "3",
                "Num. H-bond donors": "2",
                "Molar Refractivity": "85.50",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "49.69 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "2.97",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "4.35",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "3.98",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "3.17",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.05",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "3.70",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-4.42",
                "Solubility": "9.50e-03 mg/ml ; 3.37e-05 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-5.11",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-4.47",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "Yes",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.93 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.17"
            }
        },
        "4'-O-methylnyasol": {
            "PubChem ID": "23626544",
            "SMILES": "COC1=CC=C(C=C1)C=CC(C=C)C2=CC=C(C=C2)O",
            "Molecular Data": {
                "SMILES": "C=CC(c1ccc(cc1)O)C=Cc1ccc(cc1)OC",
                "Formula": "C18H18O2",
                "Molecular weight": "266.33 g/mol",
                "Num. heavy atoms": "20",
                "Num. arom. heavy atoms": "12",
                "Fraction Csp3": "0.11",
                "Num. rotatable bonds": "5",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "83.48",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "29.46 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.25",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "4.71",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "4.27",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "3.78",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "4.53",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "4.11",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-4.57",
                "Solubility": "2.36e-03 mg/ml ; 8.85e-06 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-5.06",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-5.05",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Moderately soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "Yes",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "Yes",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "Yes",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "Yes",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-4.58 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                    Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "Yes",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                   Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "Yes",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: isolated_alkene",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: XLOGP3>3.5",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "3.08"
            }
        },
        "4-hydroxyacetophenone": {
            "PubChem ID": "7469",
            "SMILES": "CC(=O)C1=CC=C(C=C1)O",
            "Molecular Data": {
                "SMILES": "CC(=O)c1ccc(cc1)O",
                "Formula": "C8H8O2",
                "Molecular weight": "136.15 g/mol",
                "Num. heavy atoms": "10",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.12",
                "Num. rotatable bonds": "1",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "38.66",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "37.30 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "1.30",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.35",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.59",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "1.12",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.68",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.41",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.91",
                "Solubility": "1.02e+00 mg/ml ; 7.46e-03 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.74",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-2.13",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "Yes",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.17 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 3 violations: MW<160, MR<40, #atoms<20",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: MW<200",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                    Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "0 alert",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "1.00"
            }
        },
        "4-hydroxybenzaldehyde": {
            "PubChem ID": "126",
            "SMILES": "C1=CC(=CC=C1C=O)O",
            "Molecular Data": {
                "SMILES": "O=Cc1ccc(cc1)O",
                "Formula": "C7H6O2",
                "Molecular weight": "122.12 g/mol",
                "Num. heavy atoms": "9",
                "Num. arom. heavy atoms": "6",
                "Fraction Csp3": "0.00",
                "Num. rotatable bonds": "1",
                "Num. H-bond acceptors": "2",
                "Num. H-bond donors": "1",
                "Molar Refractivity": "33.85",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "37.30 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "0.99",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "1.35",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "1.20",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "0.79",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "1.52",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.17",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-1.87",
                "Solubility": "2.31e+00 mg/ml ; 1.89e-02 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Very soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-1.74",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.72",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "High",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "Yes",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "No",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-6.09 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "Yes; 0 violation",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 3 violations: MW<160, MR<40, #atoms<20",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "Yes",
                "Egan \n                   Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "Yes",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 1 violation: MW<200",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.55",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: aldehyde",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW<250",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "1.00"
            }
        },
        "anemarrhenasaponin III": {
            "PubChem ID": "101672280",
            "SMILES": "CC1CCC2(C(C3C(O2)C(C4C3(CCC5C4CCC6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)O)OC8C(C(C(C(O8)CO)O)O)O)C)C)O)C)OC1",
            "Molecular Data": {
                "SMILES": "OCC1OC(OC2CCC3(C(C2)CCC2C3CCC3(C2C(O)C2C3C(C)C3(O2)CCC(CO3)C)C)C)C(C(C1O)O)OC1OC(CO)C(C(C1O)O)O",
                "Formula": "C39H64O14",
                "Molecular weight": "756.92 g/mol",
                "Num. heavy atoms": "53",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "1.00",
                "Num. rotatable bonds": "6",
                "Num. H-bond acceptors": "14",
                "Num. H-bond donors": "8",
                "Molar Refractivity": "188.00",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "217.22 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "3.85",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "2.33",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "0.41",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "-0.52",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-0.85",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "1.04",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.60",
                "Solubility": "6.62e+02 mg/ml ; 8.75e-01 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-6.53",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-0.06",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-9.26 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "No; 3 violations: MW>500, NorO>10, NHorOH>5",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 3 violations: MW>480, MR>130, #atoms>70",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "No; 1 violation: TPSA>140",
                "Egan \n                    Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "No; 1 violation: TPSA>131.6",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 5 violations: MW>600, TPSA>150, #rings>7, H-acc>10, H-don>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.17",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: saponine_derivative",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 1 violation: MW>350",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "9.32"
            }
        },
        "anemarsaponin B": {
            "PubChem ID": "132198",
            "SMILES": "CC1=C(OC2C1C3(CCC4C(C3C2)CCC5C4(CCC(C5)OC6C(C(C(C(O6)CO)O)O)OC7C(C(C(C(O7)CO)O)O)O)C)C)CCC(C)COC8C(C(C(C(O8)CO)O)O)O",
            "Molecular Data": {
                "SMILES": "OCC1OC(OC2CCC3(C(C2)CCC2C3CCC3(C2CC2C3C(=C(O2)CCC(COC2OC(CO)C(C(C2O)O)O)C)C)C)C)C(C(C1O)O)OC1OC(CO)C(C(C1O)O)O",
                "Formula": "C45H74O18",
                "Molecular weight": "903.06 g/mol",
                "Num. heavy atoms": "63",
                "Num. arom. heavy atoms": "0",
                "Fraction Csp3": "0.96",
                "Num. rotatable bonds": "13",
                "Num. H-bond acceptors": "18",
                "Num. H-bond donors": "11",
                "Molar Refractivity": "220.90",
                "TPSA\n                   Topological Polar Surface Area: Calculated from  Ertl P. et al. 2000 J. Med. Chem.": "287.14 &Aring&sup2",
                "Log Po/w (iLOGP) \n                   iLOGP: in-house physics-based method implemented from  Daina A et al. 2014 J. Chem. Inf. Model.": "4.14",
                "Log Po/w (XLOGP3) \n                   XLOGP3: Atomistic and knowledge-based method calculated by  XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry": "0.93",
                "Log Po/w (WLOGP) \n                  WLOGP: Atomistic method implemented from  Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.": "-0.83",
                "Log Po/w (MLOGP) \n                  MLOGP: Topological method implemented from  Moriguchi I. et al. 1992 Chem. Pharm. Bull.  Moriguchi I. et al. 1994 Chem. Pharm. Bull.  Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.": "-2.59",
                "Log Po/w (SILICOS-IT) \n                   SILICOS-IT: Hybrid fragmental/topological method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "-1.27",
                "Consensus Log Po/w\nConsensus Log Po/w: Average of all five predictions": "0.08",
                "Log S (ESOL) \n                 ESOL: Topological method implemented from  Delaney JS. 2004 J. Chem. Inf. Model.": "-5.17",
                "Solubility": "4.53e+03 mg/ml ; 5.01e+00 mol/l",
                "Class \n                   Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Poorly soluble",
                "Log S (Ali) \n                   Ali: Topological method implemented from  Ali J. et al. 2012 J. Chem. Inf. Model.": "-6.55",
                "Log S (SILICOS-IT) \n                   SILICOS-IT: Fragmental method calculated by  FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, https://www.silicos-it.be": "0.70",
                "Class \n                     Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly": "Soluble",
                "GI absorption \n                     Gatrointestinal absorption: according to the white of the BOILED-Egg": "Low",
                "BBB permeant \n                     BBB permeation: according to the yolk of the BOILED-Egg": "No",
                "P-gp substrate \n                   P-glycoprotein substrate: SVM model built on 1033 molecules (training set)  and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94": "Yes",
                "CYP1A2 inhibitor \n                     Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91": "No",
                "CYP2C19 inhibitor \n                     Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86  External: ACC=0.80 / AUC=0.87": "No",
                "CYP2C9 inhibitor \n                     Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85  External: ACC=0.71 / AUC=0.81": "No",
                "CYP2D6 inhibitor \n                     Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87": "No",
                "CYP3A4 inhibitor \n                     Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86": "No",
                "Log Kp (skin permeation) \n                   Skin permeation: QSPR model implemented from  Potts RO and Guy RH. 1992 Pharm. Res.": "-11.15 cm/s",
                "Lipinski \n                   Lipinski (Pfizer) filter: implemented from  Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500MLOGP ≤ 4.15N or O ≤ 10NH or OH ≤ 5": "No; 3 violations: MW>500, NorO>10, NHorOH>5",
                "Ghose \n                     Ghose filter: implemented from  Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480-0.4 ≤ WLOGP ≤ 5.640 ≤ MR ≤ 13020 ≤ atoms ≤ 70": "No; 4 violations: MW>480, WLOGP<-0.4, MR>130, #atoms>70",
                "Veber \n                   Veber (GSK) filter: implemented from  Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10TPSA ≤ 140": "No; 2 violations: Rotors>10, TPSA>140",
                "Egan \n                    Egan (Pharmacia) filter: implemented from  Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88TPSA ≤ 131.6": "No; 1 violation: TPSA>131.6",
                "Muegge \n                    Muegge (Bayer) filter: implemented from  Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600-2 ≤ XLOGP ≤ 5TPSA ≤ 150Num. rings ≤ 7Num. carbon > 4Num. heteroatoms > 1Num. rotatable bonds  ≤ 15H-bond acc. ≤ 10H-bond don. ≤ 5": "No; 5 violations: MW>600, TPSA>150, #rings>7, H-acc>10, H-don>5",
                "Bioavailability Score \n                   Abbott Bioavailability Score: Probability of F > 10% in rat  implemented from  Martin YC. 2005 J. Med. Chem.": "0.17",
                "PAINS \n                     Pan Assay Interference Structures: implemented from  Baell JB. & Holloway GA. 2010 J. Med. Chem.": "0 alert",
                "Brenk \n                     Structural Alert: implemented from  Brenk R. et al. 2008 ChemMedChem": "1 alert: saponine_derivative",
                "Leadlikeness \n                    Leadlikeness: implemented from  Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350XLOGP ≤ 3.5Num. rotatable bonds  ≤ 7": "No; 2 violations: MW>350, Rotors>7",
                "Synthetic accessibility \n                    Synthetic accessibility score:  from 1 (very easy) to 10 (very difficult)based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,trained on 12’782’590 molecules and tested on 40 external molecules (r2 = 0.94)": "10.00"
            }
        },
        "50 mg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "80℃": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "20-22% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.1 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "12-15% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "4 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "room": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "56 kg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "250 mg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "5% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "4 kg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.3 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "hot": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "5-15%  A": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "10 kg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "1.8 kg dried EtOH-soluble extract": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "20 kg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "70℃": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    },
    "지황": {
        "1-ethyl-β-d-galactoside": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "3,4-dihydroxy-O-β-d-glucopyranosyl-(1→3)-4-O-caffeoyl-β-d-glucopyranoside": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "3,4-dihydroxy-β-phenethyl-O-\n -d-glucopyranosyl-(1→3)-O-α-l-rhamno-pyranosyl-(1→6)-4-O-caffeoyl-β-d-glucopyranoside": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "3,4-dihydroxy-β-phenethyl-O-α-l-rhamnopyranosyl-\n(1→3)-O-β-d-glucopyranosyl-(1→6)-4-O-caffeoyl-β-d-glucopyranoside": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "5,6-di-hydroxy-βionone": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "acetylcatalpol": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "ajugoside": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Frehmaglutoside I": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "mannotriose": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Rhemaneolignan A": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Rhemaneolignan B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Rhemaneolignan C": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "1.0g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "정보 없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "20kg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "reflux": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "5% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    },
    "치자": {
        "1 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "boiling": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.1 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "RT, ultrasonication": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "utrasonication": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "1.0 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "ultrasonication": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "100 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "reflux": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.5 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.4 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    },
    "황금": {
        "0.1 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "10 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "15 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "2 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "50 mg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    },
    "황련": {
        "1g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "90◦C": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "10mg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.1g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "100mg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "50g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "room temperature": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.2g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "25 ºC": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    },
    "황백": {
        "(+) N-methylcorydine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "3-Feruoyl-4-caff eoylquinic acid": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "8-Oxoepiberberine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Dihydroxyl-jatrorrhizine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Hydroxyl-palmatine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Isomer of berberine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Isomer of palmatine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Isomer-of-magnofl orine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Magnofl orine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Neo-chlorogenic acid": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "Obacunone (Limonin)": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "y-fagarine and skimmianine": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.25 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "25℃": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "15% A": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "1 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "정보 없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "5% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.1 mg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "20 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "100℃": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "2.2 kg": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "이미지 없음": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.5 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "300 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "22% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "4% A": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "0.1 g": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "reflux": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        },
        "10% B": {
            "PubChem ID": "정보 없음",
            "SMILES": "정보 없음",
            "Molecular Data": "정보 없음"
        }
    }
}